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Abstract 
ABC transporters are key players in drug excretion with alterations in their 
expression and activity by therapeutic agents potentially leading to drug-drug 
interactions. The interaction potential of nomegestrol acetate (NMGA), a synthetic 
progestogen increasingly used as oral contraceptive, had never been explored. In 
this work we evaluated (1) the effect of NMGA on ABC transporters in the human 
hepatic cell line HepG2 and (2) the underlying molecular mechanism. NMGA (5, 50 
and 500 nM) increased P-glycoprotein (P-gp) expression at both protein and mRNA 
levels and reduced intracellular calcein accumulation, indicating an increase also in 
transporter activity. This up-regulation of P-gp was corroborated in Huh7 cells and 
was independent of the classical progesterone receptor. Instead, using a siRNA-
mediated silencing approach, we demonstrated the involvement of membrane 
progesterone receptor α. Moreover, we found that the activation of this receptor by 
NMGA led to a falling-rising profile in intracellular cAMP levels and protein kinase A 
activity over time, ultimately leading to transcriptional P-gp up-regulation. Finally, we 
identified inhibitory G protein and phosphodiesterases as mediators of this novel 
biphasic modulation. These results demonstrate the ability of NMGA to selectively 
up-regulate hepatic P-gp expression and activity and constitute the first report of ABC 
transporter modulation by membrane progesterone receptor α. If a similar regulation 
took place in vivo, decreased bioavailability and therapeutic efficacy of NMGA-
coadministered P-gp substrates could be expected. This holds special importance 
considering long-term administration of NMGA and broad substrate specificity of P-
gp. 
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1. Introduction 
Drug transporters belonging to the ATP binding cassette (ABC) superfamily 
play a key role in the disposition of therapeutic agents. Among them, the P-
glycoprotein (P-gp/ABCB1), the multidrug resistance-associated proteins 2 and 3 
(MRP2/ABCC2 and MRP3/ABCC3) and the breast cancer resistance protein 
(BCRP/ABCG2) transport a wide range of prescription drugs and their metabolites. In 
the liver, they localize to the canalicular membrane (P-gp, MRP2 and BCRP) or the 
basolateral membrane (MRP3) of the hepatocyte and actively extrude their 
substrates into the bile or into the liver sinusoids, respectively, thus affecting their 
pharmacokinetics [1]. Modulation of ABC transporters by drugs represents a common 
issue potentially resulting in drug-drug interactions. Increasingly preclinical and 
clinical evidence associates alterations in transporter expression with a modified 
clearance of coadministered drugs and thus with changes in their therapeutic efficacy 
and toxicity. As a well-studied example, hyperforin, a major active principle of the 
natural antidepressant St. John’s wort, induces P-gp expression and activity [2]. In 
line with this observation, a reduced bioavailability of the P-gp substrate digoxin in 
healthy volunteers receiving hyperforin has been described [3]. Similarly, modulation 
of MRP2 may also lead to unwanted drug-drug interactions. For instance, rifampicin 
has been described to induce expression of MRP2 in vivo [4] and, this way, to inhibit 
the analgesic effect of morphine [5]. Other drug-drug interactions have been 
reported, for instance, for the MRP3 substrate acetaminophen-glucuronide [6] and 
the BCRP substrate methotrexate [7]. In general, most of the reported cases of ABC 
transporter regulation by drugs can be explained in terms of activation of nuclear 
receptors or transcription factors as well as post-transcriptional mechanisms finally 
impacting in the expression levels of the different transporters [8, 9].  
  
 
 
Nomegestrol acetate (NMGA) is a potent synthetic progestogen originally used 
alone for treatment of uterine disorders or in combination with estradiol (E2) as 
hormonal replacement therapy in postmenopausal women. During the last years, a 
combination of NMGA and E2 has been approved in many countries for its use in 
oral contraception. NMGA is characterized by binding with high affinity to the 
progesterone receptor (PR) and by exhibiting high antigonadotropic activity [10, 11]. 
Unlike other progestogens used in oral contraception, NMGA does not exhibit 
androgenic effects and, in combination with E2, it displays fewer adverse effects than 
other combined oral contraceptives [12, 13]. Thus, NMGA-E2 formulations emerge 
as a promising high efficacy-few side effect combination that may gain even more 
acceptance among women and physicians in the future. Noteworthy, due to its 
relatively recent launch into the market, there is scarce information on the potential of 
NMGA to modulate ABC transporters and thus to mediate drug-drug interactions. 
This bears particular importance considering that contraceptive therapies are usually 
taken during a long part of the women’s reproductive age [14], during which other 
drugs are very likely to be coadministered.  
Progestogens mediate their physiological and pharmacological effects through 
binding to different kind of receptors. The classical progesterone receptors (PR A/B) 
are nuclear receptors exerting their effect by binding to response elements in the 
promoter of target genes [15]. The progesterone receptor membrane component 1 
(PGRMC) is part of a multi-protein progesterone-binding complex already related to 
different physiological and pathological processes [16]. Furthermore, the membrane 
progesterone receptors (mPR) are capable of activating inhibitory G protein (Gi) 
mediating both genomic and non-genomic effects [17]. The main mPR isoforms 
present in human liver are mPRα (PAQR7) and mPRγ (PAQR5), whereby PAQR7 
expression was reported to be at least 4 orders of magnitude higher than PAQR5 
  
 
 
[18]. Modulation of ABC transporters by PR has been already described [19]. 
Similarly, modulation by fluctuation of cAMP levels, one of the major downstream 
processes that could be involved after mPR activation, has been reported for P-gp 
[20], MRP2 [21] and MRP3 [22]. However, a potential association between this 
receptor and transporter regulation has not been investigated before. Since the 
activation of the above-mentioned receptors by NMGA was either demonstrated or 
seems feasible, a modulation of ABC transporters by this progestogen could be 
expected. The aim of the current work was to assess the effect of NMGA on the 
expression and activity of pharmacologically relevant ABC transporters and 
characterize the underlying molecular mechanisms.  
Our data indicates a selective up-regulation of P-gp expression and activity by 
NMGA in human hepatic cell lines. Moreover, our observations highlight the 
involvement of the mPRα in the regulatory mechanism, representing the first study 
describing a modulation of an ABC protein by an mPR. Furthermore, our results point 
to a biphasic falling-rising profile in the cAMP levels as a major mechanism 
responsible for P-gp up-regulation. 
  
 
 
2. Materials and methods 
2.1. Chemicals 
AG-205, nomegestrol acetate (NMGA), cell culture media and all supplements 
were from Sigma-Aldrich (St. Louis, USA). Ponceau S, ethanol, aprotinin, leupeptin, 
pepstatin and pefabloc were from Carl Roth (Karlsruhe, Germany). 3-isobutyl-1-
methylxanthine (IBMX), actinomycin D, calcein-AM, H-89 dihydrochloride (H89), 
KT5720, Rp-8-Br-cAMP, mifepristone (RU 486), PSC833, Ro 20-1724 and SC68376 
were from Santa Cruz Biotechnology (Heidelberg, Germany). Bordetella pertussis 
toxin (PTX) was from Enzo Life Sciences (Farmingdale, USA). PD98059 was from 
Calbiochem (San Diego, USA). Polyvinylidene difluoride (PVDF) membranes were 
from GE Healthcare (Little Chalfont, UK). DharmaFECT4 Transfection Reagent was 
from Dharmacon (Lafayette, USA). DMSO was from Merck (Darmstadt, Germany). 
All other chemicals were of analytical grade purity. 
 
2.2. Cell culture 
HepG2 cells were purchased from the American Tissue Culture Collection 
(Rockville, USA) and grown in RPMI 1640 medium supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. 
Huh7 cells were a kind gift from Prof. Dr. Ralf Bartenschlager (Heidelberg University 
Hospital, Germany) and were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 2 mM L-
glutamine, 100 U/mL penicillin and 100 µg/mL. Both cell lines were cultured at 37 °C 
in a humidified atmosphere containing 5% CO2 [23]. All experiments were performed 
with cells differing in not more than 10 passages.  
  
 
 
For the analysis of ABC transporter and mPR protein expression, P-gp, protein 
kinase A (PKA) and phosphodiesterase (PDE) activity studies, and intracellular 
cAMP determinations, cells were seeded in 6-well plates at a density of 5.0x105 
cells/well. For mRNA expression studies, cells were seeded in T25 flasks at a density 
of 1.0x106 cells/flask and cultured for 24 h. For siRNA-mediated mPRα knockdown, 
cells were seeded in 12-well plates at a density of 5.0x104 cells/well. In all cases, 
cells were cultured for 24 h after seeding and then incubated in treatment medium, 
consisting of growing culture medium and specific reagents. Particular treatment 
details are provided below in the corresponding subsection. 
 
2.3. Western blot studies 
We first evaluated the effect of NMGA on ABC transporter protein expression. 
NMGA was tested at different concentrations (0.5-500 nM) aimed to cover the 
reported range in plasma of individuals under NMGA treatment (5-40 nM) [13]. For 
this purpose, NMGA was dissolved in DMSO as a 1000x stock solution. Participation 
of PR A/B, PGRMC1 and Gi protein as mediators of NMGA effect on P-gp 
expression was explored using their inhibitors RU 486 (1 µM) [24], AG-205 (20 µM) 
[25] and PTX (200 ng/mL) [26], respectively. In order to assess the participation of 
PKA as mediator of NMGA effect, KT5720 (1 µM), H-89 (10 µM) [21] or Rp-8-Br-
cAMPS (100 µM) [27] were added to the treatment medium. To evaluate the 
involvement of p38 and ERK1/2 MAP kinases SC68376 (10 µM) [28] and PD98059 
(20 µM) [29] were used, respectively. RU 486 was dissolved in ethanol and added 
from a 10000X stock solution. AG-205, KT5720, H-89, SC68376 and PD98059 were 
dissolved in DMSO and added from 1000x stock solutions. PTX was reconstituted 
with sterile distilled water and added from a 500x stock solution. Rp-8-Br-cAMPS was 
  
 
 
dissolved in sterile distilled water and added from a 100x stock solution. The 
corresponding vehicles were used in control incubations. The final concentration of 
DMSO and ethanol in culture media was always kept below 0.2% (V/V). In all cases, 
cells were exposed to treatment medium for 48 h with exception of PKA activity 
study, in which cells were treated with 50 nM NMGA for 6 and 22 h. At the end of 
incubations, cells were harvested and subjected to western blot analysis as 
previously described by Rigalli et al. [30]. Briefly, cells were rinsed with PBS and 
incubated for 30 min in RIPA buffer (Thermo Fisher Scientific, Waltham, USA) 
supplemented with aprotinin (1 µg/mL), leupeptin (5 µg/mL), pepstatin (1 µg/mL) and 
pefabloc (1 mg/mL) as protease inhibitors. Cell lysis was accomplished by passing 
through a 25G needle. Then, lysates were subjected to protein quantification using 
the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, USA). 
Proteins were separated by SDS-PAGE, transferred onto a PVDF membrane and 
incubated in blocking buffer (3% BSA in TBS with 0.3% Tween 20) for 1 h. Then, 
membranes were sequentially incubated with primary and secondary antibody 
solutions and developed using Pierce ECL Western Blotting Substrate (Thermo 
Fisher Scientific, Waltham, USA). For low abundance protein detection (mPRγ), the 
high-sensitive WesternBright Sirius Chemiluminescent Detection Kit (Advansta Inc., 
Menlo Park, USA) was used. Finally, optical density of the bands was quantified 
using ImageJ software (NIH, Bethesda, USA). For PKA activity study, a Phosphatase 
Inhibitor Cocktail (Cell Signaling Technology, Danvers, USA) was also added to the 
RIPA buffer. For mPR detection, human liver homogenate (mixed gender, pool of 20 
donors, catalog number H0610.H) was supplied by XenoTech (Kansas City, USA) 
and HepG2 lysates were prepared from untreated cells as described above. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading 
control. Uniformity of loading and transfer was also checked through staining with 
  
 
 
Ponceau S. Primary antibodies were: anti-P-gp: C219 (1:1000) from Calbiochem 
(San Diego, USA); anti-BCRP: BXP-21 (1:1000) and anti-GAPDH: G-9 (1:1000) from 
Santa Cruz Biotechnology (Heidelberg, Germany); anti-MRP2: M2III-6 (1:1000) from 
Enzo Life Sciences (Farmingdale, USA); anti-MRP3: M3II-21 (1:1000) from Sigma-
Aldrich (Taufkirchen, Germany); anti-Phospho-(Ser/Thr) PKA substrate (9621) 
(1:1000) from Cell Signaling Technology (Danvers, USA); anti-mPRα (ab123979) 
(1:100) and anti-mPRγ (ab79517) (1:500) from Abcam (Cambridge, UK). 
 
2.4. Real time RT-PCR studies 
Cells were seeded as described in 2.2. ABCB1 mRNA level was evaluated for 
those NMGA concentrations showing alterations in P-gp protein expression. For 
ABCB1 mRNA stability study, cells were treated with NMGA (50 nM) or vehicle for 16 
h and mRNA synthesis was inhibited by adding actinomycin D (5 µg/mL). Cells were 
harvested at 0, 2, 4 and 8 h after actinomycin D addition. For PDE4D mRNA 
expression, cells were treated with NMGA (50 nM, 8 h). After treatments, cells were 
rinsed with ice cold PBS and subjected to total RNA isolation using the GenElute 
Mammalian Total RNA Miniprep kit (Sigma-Aldrich, St. Louis, USA). cDNA was 
synthesized with the RevertAid H Minus First Strand cDNA Synthesis kit (Thermo 
Fisher Scientific, Waltham, USA). The most suitable housekeeping gene was 
identified as described [30]. Among the tested housekeeping genes (hypoxanthine-
phosphoribosyltransferase 1, HPRT; ribosomal protein L13, RPL13; glucose-6-
phosphate dehydrogenase, G6PDH; β-glucuronidase, GU; RNA polymerase II, RPII 
and 60S human acidic ribosomal protein P1, HUPO), HUPO was the most stable 
under our experimental conditions. PDE4D primers were 
GGCAGGGTCAAACTGAGAAATT (forward) and TGACTGCCACTGTCCTTTTCC 
(reverse) and allow the detection of all the splicing variants of PDE4D gene [31]. 
  
 
 
PAQR7 (mPRα) primers were: CTGAAGTTTGCCTGACACCA (forward) and 
AATAGAAGCGCCAGGTCTGA (reverse). PAQR5 (mPRγ) primers were: 
GGTGCCGTCAACCTCTTC (forward) and CATCCGGGAACGTGTATG (reverse). All 
other primers used in the current work were described in Theile et al. [32]. 
 
2.5. P-gp activity assay 
P-gp activity was evaluated assessing the intracellular amount of the fluorescent 
compound calcein, which is intracellularly generated by hydrolysis of the P-gp 
substrate calcein-AM and inversely correlates with transporter activity [23, 33]. Cells 
were seeded as described in 2.2. and treated with 5-500 nM NMGA for 48 h. After 
treatment, cells were trypsinized, resuspended and incubated in growth medium 
containing the membrane permeable precursor calcein-AM (0.5 µM, 15 min). Then, 
cells were rinsed and resuspended in cold PBS. Calcein accumulation was quantified 
by flow cytometry using a Cell Sorter BD FACSAria II device (BD Biosciences, San 
Jose, USA) with a blue laser (488 nm, 20 mW) and FITC detection filter (530/30 nm). 
P-gp participation in the modulation of calcein accumulation was verified using the 
selective inhibitor PSC833 (10 µM) [33]. 
 
2.6. siRNA-mediated mPRα knockdown 
Transfection conditions regarding initial cell density, transfection reagent volume 
and siRNA concentration were optimized prior to experiments. Cells were seeded as 
described in section 2.2. Transfection media consisting of mixtures of mPRα siRNA 
(ON-TARGETplus SMARTpool siRNA, L-008033-00, Dharmacon, Lafayette, USA) or 
non-targeting control siRNA (Control siRNA-A, Santa Cruz Biotechnology, 
Heidelberg, Germany) with DharmaFECT4 Transfection Reagent (4 µL/well) were 
  
 
 
prepared according to manufacturer’s instructions to reach a final siRNA 
concentration of 50 nM. Cells were incubated in the corresponding transfection 
medium for 24 h. Then, transfection media were replaced by treatment medium 
containing NMGA (5-500 nM). Cells were further incubated for 48 h and then 
subjected to western blot analysis for mPRα, P-gp and GAPDH as described in 
section 2.3. 
 
2.7. Intracellular cAMP determination 
To evaluate the time course of intracellular cAMP levels in response to NMGA, 
cells were seeded as described in section 2.2 and incubated with treatment medium 
containing NMGA (50 nM) for 15 min, 10, 14, 18 and 24 h. To evaluate the 
participation of PDEs in the increase in cAMP levels after 14 h of treatment, we 
repeated the experiment at that time point in the presence of IBMX (500 µM, non-
selective PDE inhibitor) and Ro 20-1724 (100 µM, PDE4 selective inhibitor) [34]. 
Then, treatment medium was removed, cells were washed with PBS and lysed in HCl 
(0.1 M, 20 min) at room temperature to stop PDEs activity and stabilize the released 
cAMP [35]. Afterwards, cAMP levels were determined using cAMP Select ELISA kit 
(Cayman Chemical, Ann Arbor, USA) according to the manufacturer’s instructions.  
 
2.8. PDE activity 
To confirm PDE involvement in late intracellular cAMP increase, cells seeded as 
described in 2.2. were treated with 50 nM NMGA for 11 h. They were then rinsed with 
cold Tris buffer and lysed using NP-40 lysis buffer (150 mM NaCl, 1% Nonidet P-40, 
50 mM Tris-HCl, pH=7.4) supplemented with aprotinin (1 µg/mL), leupeptin (5 
µg/mL), pepstatin (1 µg/mL) and pefabloc (1 mg/mL) as protease inhibitors. PDE 
activity was measured in cell lysates using a colorimetric PDE Activity Assay Kit 
  
 
 
(Abcam, Cambridge, UK) based on the sequential hydrolysis of cyclic nucleotides by 
PDE and 5’ nucleotidase. The released phosphate by enzymatic cleavage is directly 
proportional to PDE activity and quantified using a modified Malachite Green reagent. 
 
2.9. Statistical analysis 
All results are expressed as mean ± standard deviation. All experiments were 
performed at least in triplicates. Statistical comparisons were performed through the 
Student's t-test or one-way ANOVA followed by Tukey post-hoc test, for 2 or more 
experimental groups, respectively. Statistical significance was set at p < 0.05. 
Statistical analysis and artwork were performed using Graph Pad Prism 7.0d (Graph 
Pad Software, La Jolla, USA). 
  
 
 
3. Results 
3.1. NMGA increases P-gp expression and activity in hepatic cell lines 
We first evaluated the effect of different concentrations of NMGA on ABC 
transporter protein expression by western blot. HepG2 cells treated with 5, 50 or 500 
nM NMGA for 48 h showed a significant, concentration-independent increase in P-gp 
expression (+83%, +77% and +93%, respectively) with respect to control cells (Fig 
1a). The inducing effect was not observed for the lowest concentration tested (0.5 
nM). The inducing effect on P-gp was confirmed in the Huh7 cell line, as treatment 
with NMGA 5, 50 and 500 nM resulted in increased protein expression (+49%, +46% 
and +67%, respectively) with respect to control cells. As in HepG2 cells, NMGA 
0.5 nM failed to increase P-gp expression (Fig 1b). BCRP, MRP2 and MRP3 protein 
expression was not affected by NMGA treatments (Fig 2). 
We further evaluated the molecular mechanisms and the pharmacological 
relevance of P-gp induction using HepG2 cells as a representative model. First, we 
quantified P-gp expression at the mRNA level by real time RT-PCR. In line with the 
previous result, an increase in ABCB1 mRNA level after 24 h treatment with 5, 50 
and 500 nM NMGA was observed (Fig 1c). ABCB1 mRNA stability was not affected 
(data not shown), suggesting a transcriptional effect of NMGA. 
To characterize the relationship between P-gp expression and activity, NMGA-
treated cells were subjected to calcein assay. The intracellular accumulation of 
calcein (which inversely correlates with P-gp activity) was significantly decreased 
after 48 h of treatment with 5, 50 and 500 nM NMGA (-25%, -28% and -23%, 
respectively), thereby indicating a higher efflux by P-gp and demonstrating the 
functional impact of NMGA-inducing effect. The reference P-gp inhibitor PSC833 
increased intracellular calcein accumulation in both control and NMGA-treated cells, 
confirming the participation of P-gp in calcein-AM efflux (Fig 1d). 
  
 
 
 
3.2. P-gp induction by NMGA is mediated by mPRα 
We first performed a screening to identify the receptor triggering P-gp up-
regulation. PR and PGRMC participation was evaluated using the pharmacological 
inhibitors RU 486 and AG-205, respectively. Since there is no mPR inhibitor available 
and considering that mPR is associated with Gi, we addressed its participation using 
the Gi protein inhibitor PTX. As represented in Fig 3a, RU 486 and AG-205 did not 
prevent NMGA-mediated P-gp up-regulation, thus ruling out the participation of PR 
and PGRMC, respectively. On the contrary, PTX prevented this effect, confirming the 
participation of a Gi protein-associated receptor and suggesting mediation by mPR.  
The specific participation of mPR in NMGA was further evaluated. First, we 
confirmed by western blot studies that mPRα is the main mPR isoform expressed in 
both human liver and HepG2 cells, whereas the γ isoform was only detected using a 
high-sensitive chemiluminescence detection reagent (Fig 3b). Higher expression of 
mPRα in human liver and HepG2 cells was also verified through real time RT-PCR 
(Fig 3c). Next, we knocked down mPRα expression using small interfering RNA 
(siRNA). In this condition, mPRα protein expression was significantly decreased (-
64%, Fig 3d) and the inducing effect of NMGA on P-gp was completely abolished, 
confirming the participation of this receptor (Fig 3e). 
 
3.3. NMGA induces a biphasic modulation of cAMP levels and PKA 
activity 
To further explore the molecular mechanism downstream the mPRα/Gi pathway, 
we evaluated the intracellular cAMP levels in NMGA-treated cells along a 24-h 
period. We found a significant decrease after 15 min of NMGA treatment (-51%, Fig 
4a), suggesting that in our model mPRα is functionally linked to Gi and results in 
  
 
 
inhibition of adenylate cyclase after ligand binding. Surprisingly, the initial decrease 
was followed by a significant increase in cAMP levels after 14 h of treatment (+131%, 
Fig 4a). This implies a novel falling-rising biphasic response in intracellular cAMP 
levels by NMGA.  
Since increased cAMP levels usually lead to protein kinase A (PKA) activation, 
we evaluated PKA activity after NMGA treatment by assessing the level of 
phosphorylation of PKA substrates. A qualitative analysis of the representative 
western blots in Fig 4b showed an overall decrease in PKA-induced phosphorylation 
levels after 6 h of treatment followed by an overall increase after 22 h. These findings 
are consistent with an early decrease in PKA activity followed by a late PKA 
activation, agreeing well with the biphasic profile exhibited by cAMP levels (Fig 4a). 
 
3.4. PKA is involved in NMGA-mediated P-gp up-regulation 
Given that treatment with NMGA resulted in modulation of PKA activity and that 
this kinase has been already demonstrated to modulate ABCB1 transcription [20, 36, 
37], we further confirmed the participation of this kinase in the effect of NMGA on P-
gp using a loss-of-function approach. Indeed, PKA inhibitors with different 
mechanism of action were used and, in all cases, P-gp induction was completely 
abolished (Fig 4c).  
Participation of p38 and ERK1/2 in P-gp induction by NMGA was also possible 
since these MAP kinases were shown to be activated by mPRα [26, 38] and to 
regulate the expression of different genes [39]. Both inhibitors used to suppress p38 
activity (SC68376) and to prevent ERK1/2 activation (PD98059) failed to prevent the 
increase in P-gp protein expression triggered by NMGA, ruling out the involvement of 
p38 and ERK1/2 kinases in this process (Fig 4c). 
  
 
 
3.5. PDEs down-regulation is involved in late cAMP increase by NMGA 
While initial cAMP decrease by NMGA treatment was expected due to Gi 
inhibitory action on adenylate cyclase, the subsequent increase in cAMP levels 
remains unexplained. Knowing that intracellular cAMP levels are determined not only 
by cAMP production by adenylate cyclase but also by cAMP degradation by PDEs, 
we repeated the cAMP measurement after 14 h of incubation with NMGA in the 
presence of PDE inhibitors. As seen in Fig 5a, the increase in intracellular cAMP 
level after 14 h of NMGA treatment was prevented by IBMX and Ro 20-1724, 
suggesting the participation of PDEs in this effect. In line with this result, we found a 
significant decrease in PDE activity towards cAMP after 11 h of NMGA treatment (-
43%, Fig 5b). Finally, NMGA decreased mRNA expression of PDE4D (-36%, Fig 5c) 
by NMGA, the main subfamily of PDE involved in cAMP turnover in human liver and 
HepG2 cells, suggesting a participation of this enzyme in the altered cAMP turn-over 
described above. 
Time-course analysis of P-gp mRNA expression exhibited a down-regulation at 6 
h, agreeing well with decreased cAMP levels at earlier incubation times (Fig 5d). 
Conversely, no changes in the mRNA levels were observed at 48 h (Fig 5d), in line 
with normalization of cAMP levels after 24 h (Fig 4a). Taken together, these findings 
provide a rationale for the biphasic modulation of cAMP levels and for the associated 
induction of P-gp by NMGA. 
  
 
 
4. Discussion 
ABC transporters play a key role in the excretion and thus in the bioavailability of 
endo- and xenobiotics, including several therapeutic drugs [1]. In the current work, 
we assessed the effect of pharmacologically relevant concentrations of NMGA on the 
expression of the major hepatic drug efflux transporters. Our data indicates no 
modulation of MRP2, MRP3 or BCRP by NMGA. Since these transporters are 
involved in the efflux of several drugs and/or their conjugated metabolites, our study 
supports the safety of NMGA towards coadministration with substrates of these 
transporters. On the contrary, our results show a significant up-regulation of P-gp 
expression and activity by NMGA in two hepatic cell lines (Fig 1a and b). In this 
regard, an increase in the expression and activity of P-gp has been already related to 
several, in part life-threatening, drug-drug interactions [8, 40, 41]. For instance, 
healthy volunteers treated with rifampicin exhibited increased hepatic P-gp 
expression with higher biliary excretion of digoxin and concomitant reduction in its 
Cmax and AUC [42]. In contrast to hepatic P-gp, in a pilot study using Caco-2 and 
LS180 intestinal cell lines, we did not observe changes in P-gp expression by NMGA 
(5-500 nM) (Tocchetti et al., unpublished results), thus suggesting a tissue-specific 
effect. Considering the long-term administration scheme of NMGA, sometimes 
through the whole reproductive age of the woman, its coadministration with other 
drugs is likely to occur. If a similar transporter up-regulation took place in vivo, higher 
hepatic clearance, reduced bioavailability and reduced therapeutic efficacy of 
coadministered drugs substrates of P-gp could be expected. 
Our results showing an increase in ABCB1 mRNA levels (Fig 1c) without changes 
in the mRNA half-life strongly suggest a transcriptional up-regulation by NMGA. A 
similar P-gp induction by progesterone was already demonstrated in porcine 
granulosa cells, being this effect mediated by the classical progesterone receptor 
  
 
 
(PR) [19]. In our model, the PR antagonist RU 486 did not prevent P-gp induction by 
NMGA (Fig 3a), suggesting a PR-independent mechanism. These observations 
could be explained in terms of the differences in the agonists and cellular milieu 
between both studies. Nuclear receptor signaling is highly dependent on the function 
of coactivators and corepressors, which exhibit a cell-specific expression pattern and 
thus provide a rationale for tissue-selective effects following exposure to a particular 
ligand [43]. Therefore, PR ability to transactivate ABCB1 promoter in granulosa cells 
may not necessary imply a similar transactivation in hepatic cells. Furthermore, 
activation of PR by NMGA in other tissues does not imply PR activation in hepatic 
cells. Interestingly, our results demonstrating a prevention of P-gp induction by PTX 
point to a Gi dependent mechanism (Fig 3a). Among progesterone receptors, mPRs 
are well-known for their association with Gi. Our results showing a prevention of P-gp 
induction by NMGA in mPRα knockdown cells (Fig 3e) further support the mediation 
by this membrane receptor. While mPR is well-known for mediating rapid and non-
genomic effects of progestogens [18], genomic effects such as the regulation of cell 
proliferation and metastasis genes [44, 45] have also been described. To our 
knowledge this is the first report on a role of mPR in the regulation of drug 
transporters. Further studies should be performed to assess whether this action also 
takes place in other tissues of pharmaco-toxicological relevance (e.g. intestine, 
blood-brain barrier).  
Membrane progesterone receptor (mPR) mechanism of action is based on the 
activation of Gi and further inhibition of adenylate cyclase, leading to decreased 
intracellular cAMP levels [17]. However, according to the literature, increased ABCB1 
transcriptional activity due to PKA activation is rather associated with increased 
intracellular levels of cAMP [36]. Intracellular levels of cAMP (and second 
messengers in general) are subject to a tight and dynamic regulation to better 
  
 
 
respond to intracellular and extracellular challenges. Therefore, we performed a time-
course study of intracellular cAMP levels after addition of NMGA. As expected from 
activation of the mPR/Gi pathway, a significant decrease was detected after 15 min 
(Fig 4a). Surprisingly, this initial decrease was followed by a significant increase 
peaking at 14 h (Fig 4a), clearly delineating a biphasic profile. Moreover, the analysis 
of PKA substrate phosphorylation (Fig 4b) as well as coincubations with 3 different 
inhibitors strongly indicate a mediation of NMGA effects by this kinase (Fig 4c).  
Regulation of intracellular cAMP levels depends on the balance between 
synthesis and degradation. In this regard, phosphodiesterases (PDEs) play a key 
role [46]. Our results using PDE inhibitors (Fig 5a) indicate involvement of PDEs in 
the effect of NMGA on intracellular cAMP levels after 14 h of incubation. Indeed, in 
the absence of PDE inhibitors, NMGA leads to an increase in cAMP levels, being the 
outcome of reduced synthesis (due to adenylate cyclase inhibition) and subsequent 
inhibited degradation (probably due to PDE down-regulation). On the contrary, PDE 
inhibitors lead, as expected, to higher basal cAMP levels and a net decrease by 
NMGA, since only cAMP synthesis is subject to modulation. We further demonstrate 
decreased PDE activity (Fig 5b) and down-regulation of PDE4D, which encodes the 
main isoform mediating cAMP turnover in liver and HepG2 cells (Fig 5c). A feedback 
between cAMP levels and PDE mRNA expression was already reported, albeit in 
other models [47, 48]. Our results strongly suggest the decrease in PDE4D 
expression as a necessary step leading to cAMP increase and thus to P-gp up-
regulation by NMGA.  
In general, women are continuously exposed to varying levels of progestogens, 
both synthetic (e.g. NMGA and other contraceptive drugs) and physiological 
(progesterone). A similar alteration of P-gp expression by other physiological and 
synthetic mPR-activating progestogens, as described for NMGA, cannot be ruled out. 
  
 
 
For instance, the contraceptive medroxyprogesterone acetate has been reported to 
signal through mPR in breast cancer cells [49]. Further studies should be performed 
to evaluate whether this interaction also takes place in hepatic cells and if, this way, 
P-gp expression can be modulated. Moreover, unpublished data from our group 
showed a similar mPRα-mediated P-gp up-regulation by progesterone in HepG2 cells 
(Tocchetti et al., unpublished results) at concentrations similar to those reported at 
the third trimester of pregnancy (100-1000 nM). Interestingly, a reduction in the 
bioavailability of drugs transported by P-gp like digoxin [50] and antiviral agents [51, 
52] has been already demonstrated during this period of pregnancy and suggests 
also a pharmacological role of P-gp modulation by progestogens in vivo.  
In conclusion, we here demonstrated an up-regulation of hepatic P-gp by the 
contraceptive progestogen NMGA. The effect takes place through a novel 
mechanism based on a mPR/Gi/adenylate cyclase-mediated down-regulation of 
intracellular cAMP levels coupled to subsequent compensatory PDE4D down-
regulation and increase in cAMP levels, ultimately leading to PKA activation and 
transcriptional induction of ABCB1. Furthermore, we demonstrated a decrease in the 
intracellular accumulation of a P-gp model substrate. Clinical studies should be 
performed to assess whether a similar regulation takes place in vivo. If so, a 
decreased bioavailability and therapeutic efficacy of coadministered drugs can be 
expected.  
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Figure legends 
Fig 1. NMGA increases P-gp expression and activity. a. Effect of NMGA on P-
gp protein expression in HepG2 cells. Cells were treated with 0.5-500 nM NMGA or 
vehicle for 48 h and then subjected to western blot analysis. b. Effect of NMGA on P-
gp protein expression in Huh7 cells. Cells were treated with 0.5-500 nM NMGA or 
vehicle for 48 h and then subjected to western blot analysis. Equal amounts of total 
protein (12 µg) were loaded in each lane. Representative blots for P-gp and GAPDH 
(loading control) are shown. Data are presented as % of control group (C) and 
expressed as mean ± standard deviation (n = 3). *Different from C, p < 0.05. c. Effect 
of NMGA on ABCB1 mRNA expression in HepG2 cells. Cells were treated with 5-500 
nM NMGA or vehicle for 24 h. Then, ABCB1 mRNA expression was assessed by real 
time RT-PCR and normalized to the expression of HUPO, used as a housekeeping 
gene. Data are presented as % of control group (C) and expressed as mean ± 
standard deviation (n = 3). *Different from C, p < 0.05. d. Effect of NMGA on P-gp 
activity in HepG2 cells. Relative fluorescence due to calcein accumulation was 
quantified by flow cytometry in control (C) and NMGA treated cells (5, 50 and 500 
nM) and inversely correlated with P-gp activity. Experiments were performed in the 
presence or absence of the selective P-gp inhibitor PSC833 (10 µM). Data are 
presented as % of C without PSC833 and expressed as mean ± standard deviation 
(n = 3). a: p < 0.05 vs C, b: p < 0.05 vs all other groups. 
Fig 2. NMGA does not modify MRP2, MRP3 and BCRP expression. Effect of 
NMGA on MRP2 (a), MRP3 (b) and BCRP (c) protein expression in HepG2 cells. 
Cells were treated with 5-500 nM NMGA or vehicle for 48 h and then subjected to 
western blot analysis. Equal amounts of total protein (12 µg) were loaded in each 
lane. Representative blots for each target protein and GAPDH (loading control) are 
  
 
 
shown. Data are presented as % of control group (C) and expressed as mean ± 
standard deviation (n = 3). 
 
Fig 3. P-gp induction by NMGA is mediated by mPRα. a. Gi, but not PR or 
PGRMC, mediates NMGA-inducing effect. Cells were treated with 5-500 nM NMGA 
or vehicle in the presence of RU 486 (RU, 1 µM), AG-205 (AG, 20 µM) and Pertussis 
toxin (PTX, 200 ng/mL) as PR, PGRMC and Gi inhibitors, respectively. Equal 
amounts of total protein (12 µg) were loaded in each lane. Representative blots for P-
gp and GAPDH (loading control) are shown. Data are presented as % of control 
group (C) and expressed as mean ± standard deviation (n = 3). *Different from the 
respective C, p < 0.05. b. HepG2 cells express mPRα. Expression of both α and γ 
isoforms of mPR was evaluated by western blot in human liver homogenates and 
HepG2 cell lysates. Equal amounts of total protein (15 µg) were loaded in each lane. 
While mPRα was easily detected in both samples, mPRγ was only detected in 
human liver by using a high-sensitive chemiluminescent detection kit. c. Comparison 
of expression of PAQR7 (mPRα) and PAQR5 (mPRγ) mRNA in human liver and 
HepG2 cells. The expression of the target genes was assessed by real time RT-PCR 
and normalized to the combined expression of HUPO, β2-microglobuline (β2-mg) 
and RNA polymerase II (RPII), used as housekeeping genes. For comparison 
purposes, data are presented as % of PAQR7 expression in human liver and 
expressed as mean ± standard deviation. Data presented are result of two 
experiments. *Different from PAQR7 expression in the same sample, p < 0.05. d. 
mPRα expression in transfected HepG2 cells. mPRα and GAPDH (loading control) 
were detected by western blot in lysates of HepG2 cells transfected either with 50 nM 
non-targeting control siRNA (C siRNA) or with 50 nM mPRα siRNA (pool of four 
  
 
 
siRNA duplexes). Equal amounts of total protein (10 µg) were loaded in each lane. 
Data are presented as % of C siRNA and expressed as mean ± standard deviation (n 
= 3). *Different from C siRNA, p < 0.05. e. mPRα is involved in NMGA-mediated P-gp 
up-regulation. Equal amounts of total protein (12 µg) were loaded in each lane. 
Representative blots for detection of P-gp and GAPDH (loading control) proteins in 
lysates of HepG2 cells transfected either with 50 nM non-targeting control or with 50 
nM mPRα siRNA are shown. Data on NMGA effects are presented as % of the 
respective C and expressed as mean ± standard deviation (n = 3). *Different from the 
respective C, p < 0.05. 
 
Fig 4. NMGA induces a biphasic modulation of cAMP levels and PKA 
activity, ultimately leading to increased P-gp expression. a. NMGA induces a 
biphasic modulation of intracellular cAMP levels. Time course of intracellular cAMP 
levels in NMGA-treated cells (dashed line) presented as % of control group (solid 
line). Cells were treated with 50 nM NMGA or vehicle during different time periods. 
Then, intracellular cAMP levels were measured using an ELISA kit. Data are 
expressed as mean ± standard deviation (n = 3). *Different from control, p < 0.05. b. 
NMGA induces a biphasic modulation of PKA activity. Phosphorylated PKA 
substrates were detected by western blot using anti-(P)-Ser/Thr PKA substrate. 
Arrows indicate proteins with altered phosphorylation status after NMGA treatment. 
Equal amounts of total protein (10 µg) were loaded in each lane. Uniformity of protein 
loading and transfer from gel to PVDF membrane was controlled with Ponceau S. c. 
PKA but not p38 or ERK1/2 is involved in NMGA-mediated P-gp up-regulation. Equal 
amounts of total protein (12 µg) were loaded in each lane. Representative blots for 
detection of P-gp and GAPDH (loading control) proteins in HepG2 cell lysates are 
  
 
 
shown. 1 µM KT5720, 10 µM H89 and 100 µM Rp-8-Br-cAMPS were used as PKA 
inhibitors. 10 µM SC68376 and 20 µM PD98059 were used as inhibitors of p38 and 
ERK1/2 activation, respectively. Data are presented as % of control group (C) and 
expressed as mean ± standard deviation (n = 3). 
Fig 5. A decrease in PDE activity underlies NMGA-mediated cAMP increase. 
a. PDEs are involved in intracellular cAMP increase after 14 h of NMGA treatment. 
Cells were treated with 50 nM NMGA or vehicle during 14 h in the presence or 
absence of PDE inhibitors (500 µM IBMX and 100 µM Ro 20-1724). Then, 
intracellular cAMP levels were measured using an ELISA kit. Data are presented as 
% of control group without inhibitors and expressed as mean ± standard deviation (n 
= 3). *Different from the respective control, p < 0.05. b. NMGA decreases PDE 
activity after 11 h of treatment. Cells were treated with 50 nM NMGA or vehicle 
during 11 h. Then, PDE activity was determined in cell lysates using a colorimetric 
assay. Data are presented as % of control group and expressed as mean ± standard 
deviation (n = 3). *Different from control, p < 0.05. c. NMGA decreases PDE4D 
mRNA expression. Cells were treated with 50 nM NMGA or vehicle for 8 h. Then, 
PDE4D mRNA expression was assessed by real time RT-PCR and normalized to 
HUPO expression. Primers were designed to detect the mRNA of all PDE4D 
isoforms. d. Time-dependence of ABCB1 mRNA regulation by NMGA. Cells were 
treated with 5-500 nM NMGA or vehicle for 6 or 48 h. Then, ABCB1 mRNA 
expression was assessed by real time RT-PCR and normalized to the expression of 
HUPO, used as a housekeeping gene. All real time RT-PCR data are presented as 
% of control group (C) and expressed as mean ± standard deviation (n = 3-4). 
*Different from C, p < 0.05. 
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